Article

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitor

2023-03-09

Abstract excerpt

SARS-CoV-2 has demonstrated extraordinary ability to evade antibody immunity by antigenic drift. Small molecule drugs may provide effective therapy while being part of a solution to circumvent SARS-CoV-2 immune escape. In this study we report an α-ketoamide based peptidomimetic inhibitor of SARS-CoV-2 main protease (M pro ), RAY1216. Enzyme inhibition kinetic analysis established that RAY1216 is a slow-tight inhi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b101aba2-885c-599c-9aaf-f6f016cd7f77
DOI: 10.1101/2023.03.09.531862

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorDOI 10.1101/2023.03.09.531862Read

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvirSemantic proximity Read

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoSemantic proximity Read

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistanceSemantic proximity Read

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.Semantic proximity Read

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacySemantic proximity Read

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332Semantic proximity Read